252723-16-3

Basic information

• Product Name: 7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyri midine
• Synonyms: 7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyri midine;4-Chloro-6-methyl-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine
• CAS NO: 252723-16-3
• Molecular Formula: C₁₃H₁₀ClN₃O₂S
• Molecular Weight: 307.76
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 252723-16-3.mol

Chemical Properties

• Boiling Point: 511.4±60.0 °C(Predicted)
• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.93±0.30(Predicted)
• CAS DataBase Reference: 7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyri midine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyri midine(252723-16-3)
• EPA Substance Registry System: 7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyri midine(252723-16-3)

Safety Data

• Hazardous Substances Data: 252723-16-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is used as a building block in the synthesis of various biologically active compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is employed as a target for medicinal chemistry research. Its pharmacological activities, including antitumor and antiviral properties, make it an interesting candidate for the development of novel therapeutic agents.
Used in Antitumor Applications:
7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is used as an antitumor agent due to its potential to inhibit the growth and progression of cancer cells. Its incorporation into drug molecules can enhance their efficacy in treating various types of cancer.
Used in Antiviral Applications:
7-Benzenesulfonyl-4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is utilized as an antiviral agent, demonstrating the ability to inhibit viral replication and reduce the severity of viral infections. Its integration into antiviral drug formulations can improve the treatment of various viral diseases.

Upstream product

• 186519-89-1 7-(benzenesulfonyl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 74-88-4 methyl iodide 
• 98-09-9 benzenesulfonyl chloride 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 35808-68-5 4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine 
• 1607005-69-5 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1229936-89-3 (2R,3S,5R)-5-(4-amino-6-methyl-5-(2-(2-methyl-5-phenylthiophen-3-yl)cyclopent-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol 

Relevant articles and documents

ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY

The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly inter

The role of alkyl substituents in deazaadenine-based diarylethene photoswitches

Diarylethenes are an important class of reversible photoswitches and often claimed to require two alkyl substituents at the carbon atoms between which the bond is formed or broken in the electrocyclic rearrangement. Here we probe this claim by the synthesis and characterization of four pairs of deazaadenine-based diarylethene photoswitches with either one or two methyl groups at these positions. Depending on the substitution pattern, diarylethenes with one alkyl group can exhibit significant photochromism, but they generally show poor stability towards extended UV irradiation, low thermal stability, and decreased fatigue resistance. The results obtained provide an important direction for the design of new efficient DNA photoswitches for the application in bionanotechnology and synthetic biology.

TREATMENT OF DRY EYE

The present disclosure provides a method of treating dry eye by inhibition of Bruton's tyrosine kinase (hereinafter "BTK") inhibitors, pharmaceutical formulations comprising the same, and processes for preparing such compounds.

Tyrosine kinase inhibitors

The present disclosure provides compounds such as pyrazolpyrimidine compounds, and pharmaceutically acceptable salts thereof, that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present

REVERSIBLE COVALENT PYRROLO- OR PYRAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT CANCER AND AUTOIMMUNE DISEASES

Oral pharmaceutical formulations comprising reversible covalent compounds having a Michael acceptor moiety, a process of their production, and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.

PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

Heterocyclic Compounds Useful as RAF Kinase Inhibitors

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use

Novel pyrrolo[2,3-d]pyrimidine compounds useful as inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 as well as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases are described.